Steven M. Paul
Steven M. Paul has made 1 open-market purchase worth $974k since Oct 22, 2026, in 1 company. The latest: $974k of RAPP, filed Oct 22, 2026, scored 69 out of 100.
Director, Rapport Therapeutics, Inc.
Follow Steven M. Paul, freeOpen the live feed
A free account gets an alert the minute a new buy or sale is filed.
Purchases
| Filed | Stock | Stake | Score | Bought | 1 week | 1 month |
|---|---|---|---|---|---|---|
| Oct 22 Form 4 (opens sec.gov) |
RAPPRapport Therapeutics, Inc. · DirectorDirector · 5 insiders buying · Near 52-week low | +86% stake | 69 | $974k 35,714 at $27.28 |
−3.4% | waiting |
Track record (hypothetical): a week after the filing, these buys averaged −3.4% (0% up, 1 measured).
Questions
What stock has Steven M. Paul bought?
RAPP (Rapport Therapeutics, Inc.), all on the open market and reported on SEC Form 4.
When did Steven M. Paul last buy?
Oct 22, 2026: 35,714 shares of RAPP at $27.28, $974k in all (Form 4 (opens sec.gov)).
Has Steven M. Paul filed a notice of a planned sale?
Not in the filings on record. A Form 144 is the notice an insider must file before selling restricted or control shares, and it lands on EDGAR before the sale is reported.
Is Steven M. Paul a routine or an opportunistic buyer?
There isn't enough history to say yet.
Data as of Oct 22, 2026, from SEC EDGAR Form 4 filings: open-market purchases (code P) of $25,000 or more, and open-market sales. Every row links to its filing. Scores summarise what a filing says (how the score works); outcomes are hypothetical, from the first close after the filing, and past results don't predict future ones. Disclaimer